Conference Reports for NATAP

Back

HIV Glasgow 2026 8-11 November     Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow - (11/04/26)   Comorbidity/Aging Prescription Medication Use, Comorbidity Burden, and Drug-Drug Interaction Potential Among People with HIV in a Large US Claims Database (2024) - (11/09/26)   Metabolic and Liver Outcomes Through Week 48 Following Switch to Dolutegravir/Lamivudine in Older, ART-Experienced Adults: The Phase 3b EYEWITNESS Study - (11/09/26)   PrEP Higher Persistence on Twice-Yearly Lenacapavir Versus Daily F/TDF for PrEP in the UK and France in the PURPOSE 5 Study - (11/09/26)   ART subsection The Evolution of Integrase Strand Transfer Inhibitors: VH-184, a 3rd-Generation Inhibitor With an Enhanced Resistance Profile - (11/09/26)   Comparative Efficacy and Safety of Doravirine/Islatravir versus Contemporary ART Regimens in Virologically Suppressed People Living with HIV-1 at 48 Weeks: A Systematic Review and Network Meta-Analysis - (11/09/26)   Patient-Reported Outcomes With Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV-1: Phase 3 Results Through Week 96 - (11/09/26)   Resistance Analysis at Week 48 of Daily Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Blinded Phase 3 Study in Adults Initiating Treatment for HIV-1 - (11/09/26)   Evaluation of Weight at Week 48 in a Phase 3 Study in Adults Initiating Treatment for HIV-1 With Doravirine/Islatravir (100 mg/0.25 mg) versus Bictegravir/Emtricitabine/Tenofovir Alafenamide - (11/09/26)   Understanding Treatment Experiences with Weekly Oral Islatravir/Lenacapavir in the Phase 3 ISLEND-2 Study: Participant and Provider Interviews - (11/09/26)   Quality of Life and Treatment Preference With Weekly ISL/LEN Versus Standard of Care: Week 48 Patient-Reported Outcomes of the Phase 3 ISLEND-2 Study - (11/09/26)   Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Standard of Care Across Participant Subgroups Through Week 48 in the Phase 3 ISLEND-2 Trial - (11/09/26)   Once-Weekly Oral Islatravir/Lenacapavir Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults With HIV-1: Week 48 Subgroup Analyses of the Phase 3 ISLEND-1 Trial - (11/09/26)   Antiviral Activity, Pharmacokinetics, and Safety of Oral GS-3242 for HIV-1 Treatment - (11/09/26)